Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RARX Ra Pharmaceuticals (RARX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Ra Pharmaceuticals Stock (NASDAQ:RARX) 30 days 90 days 365 days Advanced Chart Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Ra Pharmaceuticals alerts:Sign Up Key Stats Today's Range$47.99▼$47.9950-Day Range$47.99▼$48.0052-Week Range$19.64▼$48.02Volume30,200 shsAverage Volume1.16 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.Read More… Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Receive RARX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RARX Stock News HeadlinesDeepCure links with Leeds Institute to bring AI-based RA drug to clinicAugust 20, 2024 | msn.comRA: Discount Continues To Leave Some OpportunityJanuary 23, 2024 | seekingalpha.comTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.November 21, 2024 | Weiss Ratings (Ad)Imperial Petroleum, ARS Pharmaceuticals Stock, and More See Action From Activist InvestorsSeptember 8, 2023 | barrons.comAnthera Pharmaceuticals (ANTH) Stock Dropping After Pricing Public OfferingMay 29, 2023 | thestreet.comUPDATE 1-AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln dealJanuary 10, 2023 | msn.comRA Capital Closes Position in Astria Therapeutics (ATXS)November 15, 2022 | 247wallst.comRARX_old Historical DataAugust 20, 2022 | investing.comSee More Headlines RARX Stock Analysis - Frequently Asked Questions How were Ra Pharmaceuticals' earnings last quarter? Ra Pharmaceuticals Inc (NASDAQ:RARX) released its earnings results on Thursday, February, 27th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.16. When did Ra Pharmaceuticals IPO? Ra Pharmaceuticals (RARX) raised $75 million in an initial public offering on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager. What other stocks do shareholders of Ra Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ra Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Verastem (VSTM), Amarin (AMRN), Bausch Health Companies (BHC) and Galmed Pharmaceuticals (GLMD). Company Calendar Last Earnings2/27/2020Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:RARX CUSIPN/A CIK1481512 Webwww.rapharma.com Phone617-401-4060FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,690,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.61% Return on Assets-41.60% Debt Debt-to-Equity Ratio0.01 Current Ratio14.78 Quick Ratio14.79 Sales & Book Value Annual Sales$3 million Price / Sales757.11 Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book8.63Miscellaneous Outstanding Shares47,329,000Free FloatN/AMarket Cap$2.27 billion OptionableOptionable Beta1.05 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:RARX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ra Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ra Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.